Analis is proud to announce a new partnership with PixCell Medical, an innovator in point-of-care hematology testing. This collaboration brings the HemoScreen™, the first FDA-cleared, IVDR CE-mark-approved 5-part differential CBC analyzer for POCT, to the Belux market.
With results in under five minutes from a simple finger-prick sample, the HemoScreen™ provides lab-grade accuracy in a portable, user-friendly format. It's a game changer for (de)centralized laboratories, oncology clinics, pediatric units, ICU/emergency rooms, psychiatric units, and primary care, where fast, reliable diagnostics are critical.
This partnership reflects Analis's ongoing mission to deliver high-quality, innovative solutions that improve diagnostic workflows and patient outcomes.
Discover how HemoScreen™ enhances point-of-care testing
